The initial rationale behind BZ development and use was its inhibition of the inducible IκBα degradation by 26S proteasome, resulting in the inhibition of nuclear translocation of NFκB subunits and decreased expression of NFκB-dependent anti-apoptotic genes in multiple myeloma cells [21, 22]. Here, NFKBIA is linked to plasma cell myeloma.